Urgent

Multiple endocrine neoplasia type 2 (MEN2)

MEN2 · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Autosomal dominant RET proto-oncogene syndrome causing medullary thyroid carcinoma, phaeochromocytoma and (type 2A) hyperparathyroidism. Genotype-directed prophylactic thyroidectomy prevents medullary thyroid cancer death.

Red flags

  • Undetected phaeochromocytoma before thyroid/parathyroid surgery
  • Rising calcitonin (persistent/recurrent medullary carcinoma)
  • Hypertensive crisis
  • Distant metastatic medullary thyroid carcinoma
  • Severe hypocalcaemia after thyroidectomy

Assessment

Differential diagnosis

  • Sporadic medullary thyroid carcinoma
  • MEN1
  • Sporadic phaeochromocytoma
  • Familial medullary thyroid carcinoma
  • Neurofibromatosis-associated tumours

Investigations

  • Calcitonin and carcinoembryonic antigen (medullary thyroid carcinoma)
  • Plasma/urinary metanephrines before any surgery
  • Calcium and PTH (type 2A)
  • Neck ultrasound and functional imaging for staging
  • Germline RET mutation testing and cascade screening

Management

  • Confirm diagnosis with RET genetic testing and stratify by codon-specific risk
  • Always exclude phaeochromocytoma before any surgery
  • Offer risk-stratified prophylactic total thyroidectomy (timing by RET genotype)
  • Resect established medullary thyroid carcinoma with appropriate nodal dissection
  • Treat phaeochromocytoma with alpha-blockade then adrenalectomy before thyroid surgery
  • Manage hyperparathyroidism (type 2A) when present
  • Monitor calcitonin/CEA trends for persistent/recurrent disease
  • Use RET-selective kinase inhibitors for advanced/progressive medullary thyroid carcinoma
  • Cascade-test relatives and offer early intervention to gene carriers
  • Provide lifelong surveillance and genetic counselling

Drugs & doses

Levothyroxine replacement after thyroidectomy
Alpha-blocker (phenoxybenzamine/doxazosin) before phaeochromocytoma surgery
Selpercatinib or pralsetinib (RET inhibitors) for advanced medullary thyroid carcinoma
Calcium/vitamin D for post-surgical hypoparathyroidism

Disposition

Manage in a specialist endocrine-surgical centre with genetics; prioritise phaeochromocytoma exclusion and arrange cascade family testing and lifelong follow-up.

Complications & pitfalls

  • Metastatic medullary thyroid carcinoma
  • Phaeochromocytoma crisis
  • Post-thyroidectomy hypoparathyroidism/recurrent laryngeal nerve injury
  • Recurrent hyperparathyroidism
  • Treatment-related toxicity

Exam pearls

  • Always exclude phaeochromocytoma before operating; adrenal surgery precedes thyroid surgery
  • Prophylactic thyroidectomy timing is dictated by the specific RET codon
  • Calcitonin and CEA trends track medullary thyroid carcinoma burden
  • Highest-risk RET mutations warrant thyroidectomy in infancy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.